
|Articles|December 1, 2012
Active surveillance an evolving approach for low-risk prostate cancer
In this interview, Laurence Klotz, MD, discusses his group's active surveillance protocol for men with favorable-risk prostate cancer, which men are candidates, how they are monitored, and triggers for active treatment.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves tebipenem pivoxil for complicated urinary tract infections
2
Louise Emmett, MD, PhD, highlights early data on 225Ac-PSMA-617 in mCRPC
3
Jenny Guo, MD, discusses outcomes with hemi-HoLEP after pelvic radiation
4
Daniel Eun, MD, on telesurgery, AI, and the future of reconstructive urology
5











